Potential drug interaction of corticosteroids and symptomatic therapy in COVID-19 patients in RSUD Banyumas, Indonesia

Corticosteroids may interact with another drug used in COVID-19 treatment. Drug-drug interactions can diminish the efficacy of drugs in the body, necessitating proper management. This study aimed to identify potential drug interactions in COVID-19 therapy at Banyumas Hospital, Indonesia. This study implemented descriptive observational methodology with a retrospective design. The study included all COVID-19 inpatients at the Banyumas Hospital between June 2020 and June 2021. Potential drug interactions were analyzed using the Drugs Interaction Checker on Drugs.com and Lexicomp on UpToDate. Among 334 patients, pharmacokinetics (189 cases, 38.10%), pharmacodynamics (264 cases, 53.23%), and unknown (44 cases, 8.87%) drug interaction may occur. Based on the severity, the potential for drug interactions were classified as significant (50 cases, 10.08%), moderate (204 cases, 41.13%), and minor (243 cases, 48.1%). Patients with COVID-19 are at risk for potential drug interactions, most of which cannot be avoided. It is important to select appropriate drug uses and manage therapy appropriately to reduce the incidence of potential drug interactions.